J
Jeppe Schroll
Researcher at Hvidovre Hospital
Publications - 31
Citations - 1803
Jeppe Schroll is an academic researcher from Hvidovre Hospital. The author has contributed to research in topics: Medicine & Meta-analysis. The author has an hindex of 13, co-authored 20 publications receiving 1524 citations. Previous affiliations of Jeppe Schroll include Rigshospitalet & Copenhagen University Hospital.
Papers
More filters
Journal ArticleDOI
Industry sponsorship and research outcome
TL;DR: The analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments.
Journal ArticleDOI
Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study
Julie Bolette Brix Bindslev,Julie Bolette Brix Bindslev,Jeppe Schroll,Jeppe Schroll,Peter C Gøtzsche,Peter C Gøtzsche,Andreas Lundh,Andreas Lundh +7 more
TL;DR: The prevalence and underreporting of conflicts of interest among authors of clinical guidelines on drug treatments in Danish clinical specialty societies was determined using a public available disclosure list.
Journal ArticleDOI
Industry sponsorship and research outcome: systematic review with meta-analysis
Andreas Lundh,Andreas Lundh,Andreas Lundh,Joel Lexchin,Barbara Mintzes,Jeppe Schroll,Lisa Bero +6 more
TL;DR: Drug and device studiessponsored by manufacturing companies have more favorable efficacy results and conclusions than studies sponsored by other sources, compared with studies having other sources of sponsorship.
Reference EntryDOI
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Bianca Hemmingsen,Jeppe Schroll,Søren S Lund,Jørn Wetterslev,Christian Gluud,Allan Vaag,David P. Sonne,Lars Hyldborg Lundstrøm,Thomas Almdal +8 more
TL;DR: To assess the effects of sulphonylurea monotherapy versus placebo, no intervention or other antidiabetic interventions for patients with T2DM, 72 randomised controlled trials were included and the risk of bias was evaluated.
Journal ArticleDOI
Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis
Bianca Hemmingsen,Jeppe Schroll,Jørn Wetterslev,Christian Gluud,A. Vaag,David P. Sonne,Lars Hyldborg Lundstrøm,Thomas Almdal +7 more
TL;DR: Some evidence suggests that, compared with metformin, second- and third-generation sulfonylureas may not affect all-cause or cardiovascular mortality but may decrease the risk of nonfatal macrovascular outcomes among patients with type 2 diabetes.